Why the study?
Clinical observations suggest oral dantrolene may relieve myopathic symptoms in malignant hyperthermia-susceptible patients, but high-dose oral dantrolene has been associated with severe hepatotoxicity.
Does oral dantrolene safely improve myopathic symptoms in malignant hyperthermia-susceptible patients?
Population
164 MHS patients with positive CHCT and myopathic manifestations who started oral dantrolene
Comparison
Oral dantrolene therapy
Design
Retrospective database review cohort study
Authors
Loading...
Oral dantrolene appears tolerable without serious adverse effects in MHS myopathy; leaves open efficacy for randomized trials.
Does oral dantrolene safely improve myopathic symptoms in malignant hyperthermia-susceptible patients?
Oral dantrolene appears safe and well-tolerated for symptomatic relief of myopathic symptoms in malignant hyperthermia-susceptible patients, with 87% reporting clinical improvement.
Moreno et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: